Pasithea Therapeutics Corp (KTTA) FinancialsKTTAFinancialPasithea Therapeutics Corp

Evaluating the bottom line, Pasithea Therapeutics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -58.22%, provide a clear picture of how effectively KTTA converts its operational activities into shareholder value.

In the context of the broader market, KTTA competes directly with industry leaders such as PTN and QCLS. With a market capitalization of $16.06M, it holds a significant position in the sector. When comparing efficiency, KTTA's gross margin of N/A stands against PTN's 100.00% and QCLS's N/A. Such benchmarking helps identify whether Pasithea Therapeutics Corp is trading at a premium or discount relative to its financial performance.

Pasithea has shown significant losses in net income, with a net income of -$10,110,868 in Q4 2025. However, the current ratio is strong at 35.40, indicating good liquidity. The company is also a penny stock, which typically carries higher risk.